Selective androgen receptor modulator for treating hormone-related conditions
View Patent ↗This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy.
1. A method of treating a hormone-related condition associated with androgen deficiency in a female (ADIF), the method comprising administering a compound of formula (III)
or its optical isomer, pharmaceutically acceptable salt, pharmaceutical product, hydrate, or any combination thereof,
wherein said condition associated with ADIF is sexual dysfunction, decreased sexual libido, hypogonadism, alterations in cognition and mood, and depression.
2. A method of treating a hormone-related condition associated with androgen deficiency in aging male (ADAM), the method comprising administering a compound of formula (III)
or its optical isomer, pharmaceutically acceptable salt, pharmaceutical product, hydrate, or any combination thereof,
wherein said condition associated with ADAM is fatigue, depression, decreased sexual libido, sexual dysfunction, erectile dysfunction, hypogonadism, and alterations in mood and cognition.
3. A method of treating decreased sexual libido, the method comprising administering to a female subject in need thereof a compound of formula (III)
or its optical isomer, pharmaceutically acceptable salt, pharmaceutical product, hydrate, or any combination thereof.
4. A method of treating decreased sexual libido, the method comprising administering to a male subject in need thereof a compound of formula (III)
or its optical isomer, pharmaceutically acceptable salt, pharmaceutical product, hydrate, or any combination thereof.